Search
forLearn
5 / 801 resultslearn sh-Polypeptide-7
learn ACETYL TETRAPEPTIDE-2
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn Pea peptides
Research
5 / 1000+ results
research Phospholipase A2 Is Required for PIN-FORMED Protein Trafficking to the Plasma Membrane in theArabidopsisRoot
Phospholipase A2 is necessary for the correct placement of PIN proteins in plant roots, affecting root growth.
research IL-17 axis is a significant driver of skin inflammation in Card14 mutant pityriasis rubra pilaris model mice
Blocking IL-17 can reduce skin inflammation in a mouse model of pityriasis rubra pilaris.
research Phospholipase A2 in skin biology: new insights from gene-manipulated mice and lipidomics
Phospholipase A2 enzymes play key roles in skin health and disease.
research Fatty acids and related lipid mediators in the regulation of cutaneous inflammation
Certain fats in the skin help control inflammation and health, and changing these fats through diet or supplements might treat skin inflammation.
research Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists
Formyl-peptide receptor agonists could be new anti-inflammatory drugs.
Community Join
5 / 1000+ resultscommunity Setipiprant/PGE2 feedbacks?
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community How long are Pelage going to milk the phase 2a results of PP405?
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.